Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Business Alignment PCLBKK:BIZ-R -0.83%91 Debt-to-EBITDA is 0.75 as of Jun. 2026, which is 15% below its 10-year median of 0.88. GuruFocus rates BKK:BIZ-R with a GF Score™ of 91/100 and a GF Value™ of ฿5.44. The stock has 5 warning signs investors should review. Among 478 Medical Devices & Instruments companies, Business Alignment PCL ranks better than 69.46% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Business Alignment PCL's Debt-to-EBITDA or its related term are showing as below:
BKK:BIZ-R'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.4 Med: 0.88 Max: 5.64
Current: 0.6
During the past 11 years, the highest Debt-to-EBITDA Ratio of Business Alignment PCL was 5.64. The lowest was 0.40. And the median was 0.88.
BKK:BIZ-R's Debt-to-EBITDA is ranked better than 69.46% of 478
companies
in the Medical Devices & Instruments industry
Industry Median: 1.65
vs BKK:BIZ-R: 0.60
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Business Alignment PCL Debt-to-EBITDA Related Terms
Business Alignment PCL Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Business Alignment PCL's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:BIZ-R vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Business Alignment PCL's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Business Alignment PCL Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Business Alignment PCL's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Business Alignment PCL's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Business Alignment PCL (BKK:BIZ-R) has a Debt-to-EBITDA of 0.75 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Business Alignment PCL. This is 15% below median its historical median of 0.88. Over the past decade, Business Alignment PCL's Debt-to-EBITDA has ranged from 0.40 to 5.64. According to the industry distribution chart, Business Alignment PCL ranks #146 out of 478 companies in the Medical Devices & Instruments industry, placing it in the top 30.5%.
Is Business Alignment PCL's Debt-to-EBITDA too high?
Business Alignment PCL's current Debt-to-EBITDA of 0.75 is 15% below median its 10-year median of 0.88. Over the past 10 years, this metric has ranged from a low of 0.40 to a high of 5.64. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.65. Business Alignment PCL's value of 0.75 is 54.5% below this industry median. Based on the distribution chart, Business Alignment PCL ranks #146 out of 478 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Business Alignment PCL has a GF Score™ of 91/100, reflecting its overall financial health beyond just this single metric.
How does Business Alignment PCL's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Business Alignment PCL ranks #146 out of 478 companies for Debt-to-EBITDA. This puts Business Alignment PCL in the upper half of its industry. The industry median Debt-to-EBITDA is 1.65. Business Alignment PCL's value of 0.75 is 54.5% below this benchmark. Historically, Business Alignment PCL's own Debt-to-EBITDA has ranged from 0.40 to 5.64 over the past decade. While the company's 10-year median is 0.88 vs. the industry median of 1.65, Business Alignment PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.65, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Business Alignment PCL's current Debt-to-EBITDA of 0.75 is 54.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Business Alignment PCL. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Business Alignment PCL's current Debt-to-EBITDA is 0.75, which is 15% below median its own 10-year median of 0.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Business Alignment PCL stock overvalued right now?
Business Alignment PCL (BKK:BIZ-R) has a current Debt-to-EBITDA of 0.75. The stock's GF Value™ is ฿5.44, compared to a current price of ฿5.95 — trading 9.4% above its estimated fair value. The current Debt-to-EBITDA is 0.75, which is 15% below median its 10-year median of 0.88 and 54.5% below the Medical Devices & Instruments industry median of 1.65. Business Alignment PCL's overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Business Alignment PCL (BKK:BIZ-R), the current Debt-to-EBITDA is 0.75 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Business Alignment PCL (BKK:BIZ-R) Overvalued in 2026?
Based on GuruFocus' analysis, Business Alignment PCL stock appears to be overvalued.
The current stock price of ฿5.95 is trading 9.4% above its estimated GF Value™ of ฿5.44.
Key valuation signals for BKK:BIZ-R:
Debt-to-EBITDA: 0.75 (15% below median its 10-year median of 0.88)
GF Value™: ฿5.44 vs. price of ฿5.95 (9.4% above fair value)
Industry Position: 54.5% below the Medical Devices & Instruments median (#146 of 478)
No single metric tells the full story. See the BKK:BIZ-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Business Alignment PCL is engaged in the distribution and installation of medical equipment for cancer treatment through radiotherapy. The company operates through the sale of medical equipment segment which includes installation, repair, and maintenance. In addition, it also focuses on increasing the efficiency of medical equipment; and Hospital operations (specialized in cancer treatment). The company is a distributor for Radiotherapy products and Brachytheraphy products in Thailand and Cambodia. Geographically, it operates in the region of Thailand.
91GF Score
Get the complete analysis for BKK:BIZ-R
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:BIZ-R has been successfully added to your 
